MeiraGTx Q3 net loss $25.9M ($0.59/sh); cash $143.6M; R&D spend jumps

MeiraGTx Holdings plc

2021-Q3 EPS reported -$1.58 revenue$16,658,000

Net loss $25.9M ($0.59 loss per share) vs $6.4M ($0.17) YoY; license revenue $6.9M.
R&D expenses surged to $21.6M from $4.6M on clinical trial and manufacturing costs.
Cash and equivalents $143.6M; expects funding into Q2 2023.
Phase 3 Lumeos trial for XLRP screening; AQUAx xerostomia Phase 1 enrollment to complete Q4 2021.
IND planned for AAV-GAD in Parkinson's and Phase 3 pivotal trial for AAV-RPE65 in early 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.